Stockreport

Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand [Yahoo! Finance]

Waldencast Acquisition Corp. - Class A Ordinary Share  (WALD) 
PDF U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling it [Read more]